glp 1 agonist or antagonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data GLP-1 Receptor Agonists as Treatments

Short-acting drugs include exenatide twice daily, lixisenatide once daily and oral semaglutide once daily, while long-acting drugs include liraglutide, semaglutide, exenatide, albiglutide and dulaglutide all being administered once weekly

placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1) Diabet

Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zemel BS

The Hidden Limitations of GLP-1-Only Weight Loss 1

Once administered, the medication targets the hypothalamus- the brains hunger control center to effectively quiet intrusive thoughts about food and lower your biological urge to eat